SLDB (Solid Biosciences Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SLDB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | IAN F SMITH | Director | M | — | — |
| 2026-06-11 | Martin I Freed | Director | A | — | — |
| 2026-06-11 | Adam Leo Stone | Director | A | — | — |
| 2026-06-11 | IAN F SMITH | Director | A | — | — |
| 2026-06-11 | Clare Kahn | Director | A | — | — |
| 2026-06-11 | Sukumar Nagendran | Director | A | — | — |
| 2026-06-11 | Georgia Keresty | Director | A | — | — |
| 2026-06-11 | Lynne Marie Sullivan | Director | A | — | — |
| 2026-06-11 | PERCEPTIVE ADVISORS LLC | Director | A | — | — |
| 2026-06-11 | Ilan Ganot | Director | A | — | — |
| 2026-04-21 | Gabriel Brooks | Chief Medical Officer | A | — | — |
| 2026-04-21 | Paul Herzich | Chief Technology Officer | A | — | — |
| 2026-04-21 | David T Howton | Chief Operating Officer | A | — | — |
| 2026-04-21 | Alexander Cumbo | President and CEO | A | — | — |
| 2026-04-21 | Jessie Hanrahan | Chief Regulatory Officer | A | — | — |
| 2026-04-21 | Kevin Tan | CFO & Treasurer | A | — | — |
| 2026-04-02 | IAN F SMITH | Director | M | — | — |
| 2026-03-11 | JOSEPH EDELMAN | Director | A | — | — |
| 2026-02-18 | Gabriel Brooks | Chief Medical Officer | MIXED | — | — |
| 2026-02-18 | Alexander Cumbo | President and CEO | MIXED | — | — |
| 2026-02-18 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | — | — |
| 2026-02-18 | Kevin Tan | CFO & Treasurer | MIXED | — | — |
| 2026-02-18 | Paul Herzich | Chief Technology Officer | MIXED | — | — |
| 2026-02-18 | David T Howton | Chief Operating Officer | MIXED | — | — |
| 2026-02-18 | Ilan Ganot | Director | MIXED | — | — |
| 2026-02-06 | Gabriel Brooks | Chief Medical Officer | Sell | — | — |
| 2026-02-06 | David T Howton | Chief Operating Officer | Sell | — | — |
| 2026-02-06 | Ilan Ganot | Director | Sell | — | — |
| 2026-02-06 | Paul Herzich | Chief Technology Officer | Sell | — | — |
| 2026-02-06 | Kevin Tan | CFO & Treasurer | Sell | — | — |
| 2026-02-06 | Alexander Cumbo | President and CEO | Sell | — | — |
| 2026-02-06 | Jessie Hanrahan | Chief Regulatory Officer | Sell | — | — |
| 2026-02-02 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | — | — |
| 2026-02-02 | Ilan Ganot | Director | M | — | — |
| 2026-02-02 | Alexander Cumbo | President and CEO | MIXED | — | — |
| 2026-02-02 | Kevin Tan | CFO & Treasurer | MIXED | — | — |
| 2026-02-02 | Paul Herzich | Chief Technology Officer | MIXED | — | — |
| 2026-02-02 | Gabriel Brooks | Chief Medical Officer | MIXED | — | — |
| 2026-02-02 | David T Howton | Chief Operating Officer | MIXED | — | — |
| 2026-01-30 | Ilan Ganot | Director | MIXED | — | — |
| 2026-01-13 | Kevin Tan | CFO & Treasurer | MIXED | — | — |
| 2026-01-07 | IAN F SMITH | Director | M | — | — |
| 2026-01-06 | Ilan Ganot | Director | MIXED | — | — |
| 2025-12-04 | David T Howton | Chief Operating Officer | MIXED | — | — |
| 2025-12-04 | Jessie Hanrahan | Chief Regulatory Officer | MIXED | — | — |
| 2025-12-04 | Alexander Cumbo | President and CEO | MIXED | — | — |
| 2025-12-04 | Paul Herzich | Chief Technology Officer | MIXED | — | — |
| 2025-11-13 | Ilan Ganot | Director | Sell | — | — |
| 2025-10-21 | Gabriel Brooks | Chief Medical Officer | MIXED | — | — |
| 2025-10-07 | IAN F SMITH | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,034,582 | — |
| — | 10%+ Owner | 4,248,084 | — |
| — | Director | 4,192,216 | — |
| — | Director | 4,034,582 | — |
| — | Director | 4,034,582 | — |
| — | Director | 772,019 | — |
| — | Director | 449,987 | — |
| — | Director | 262,229 | — |
| — | 10%+ Owner | 236,183 | — |
| — | President and CEO | 235,405 | — |
| — | 10%+ Owner | 231,551 | — |
| — | Director | 138,145 | — |
| — | Director | 129,429 | — |
| — | Chief Operating Officer | 105,077 | — |
| — | CFO & Treasurer | 104,826 | — |
| — | Chief Medical Officer | 95,029 | — |
| — | Chief Regulatory Officer | 78,452 | — |
| — | Chief Technology Officer | 76,254 | — |
| — | Director | 73,107 | — |
| — | Director | 73,107 | — |
| — | Director | 73,107 | — |
| — | Director | 46,753 | — |
| — | CFO, Treasurer & Asst. Secy | 22,376 | — |
| — | Chief Scientific Officer | 20,201 | — |
| — | Chief Operating Officer | 16,769 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLDB quote page; the site-wide leaderboard is on the insider transactions hub.